



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										ATTY. DOCKET NO. PC10760A										SERIAL NO. 09/883,752									
										APPLICANT J. C. KATH																			
										FILING DATE JUNE 18, 2001										GROUP 1614									
U.S. PATENT DOCUMENTS																													
EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME								CLASS	SUBCLASS	FILING DATE IF APPROPRIATE								
MB		6	2	2	5	3	1	8	5/2001	Sobolov-Jaynes																			
FOREIGN PATENT DOCUMENTS																													
DOCUMENT NUMBER										DATE	COUNTRY										CLASS	SUBCLASS	TRANSLATION						
																							YES	NO					
MB		9	6	1	5	1	1	8	5/96	WIPO																			
MB		9	7	3	0	0	3	4	8/97	WIPO																			
MB		9	9	3	5	1	3	2	7/99	WIPO																			
MB		9	9	3	5	1	4	6	7/99	WIPO																			
MB		0	0	2	1	9	5	5	4/00	WIPO																			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																													
MB		Vincent, et al.; Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts; Cancer Chemother Pharmacol; 45:231-238 (2000).																											
MB		Showalter, et al.; Tyrosine Kinase Inhibitors; J. Med. Chem.; 42:5464-5474 (1999).																											
MB		Hennequin, et al.; Design and Structure - Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors; J. Med. Chem.; 42:5369-5389 (1999).																											
MB		Wedge, et al.; ZD4190: An Orally Active Inhibitor of Vascular Endothelial Growth Factor Signaling with Broad-Spectrum Antitumor Efficacy; Cancer Research; 60:970-975 (2000).																											
EXAMINER										DATE CONSIDERED																			
MB										12/30/02																			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																													

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE